CRL-40,940

CRL-40,940

CRL-40,940

Wakefulness-promoting drug/Dopamine reuptake inhibitor

CRL-40,940 (also known as flmodafinil, bisfluoromodafinil and lauflumide) is the bisfluoro analog of modafinil.[1][2][3][4][5] It is a eugeroic as well as a weak dopamine reuptake inhibitor. Its inventors claim that it is more effective than modafinil and adrafinil, with fewer side effects. It was patented in 2013, and pre-clinical trials have been underway since December 2015.[6]

Quick Facts Identifiers, CAS Number ...

See also

References

  1. [1]
    CA 1199916, Lafon L, "Benzhydrylsulfinylacetamide derivatives", published 28 January 1986
  2. [2]
    Cao J, Prisinzano TE, Okunola OM, Kopajtic T, Shook M, Katz JL, Newman AH (October 2010). "Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues". ACS Medicinal Chemistry Letters. 2 (1): 48–52. doi:10.1021/ml1002025. PMC 3041981. PMID 21344069.
  3. [3]
    US 20130295196, Konofal E, "Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof", published 7 November 2013
  4. [4]
    "Flmodafinil Dosage: How Much Should You Take and When?". modaforum.org. Retrieved 2023-09-26.
  5. [5]
    Louis Lafon (18 December 1984). "Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids". Retrieved 25 July 2015.
  6. [6]
    "Pipeline". NLS Pharmaceuticals.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article CRL-40,940, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.